Considering renal risk while managing cancer

References

• American Cancer Society2015Survival rates for prostate cancer Available from: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-survival-ratesAccessed March 16, 2015
   Google Scholar
• Cancer Research UK2011Prostate cancer survival statistics Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/survival/prostate-cancer-survival-statisticsAccessed March 16, 2015
   Google Scholar
• American Cancer Society2015Breast cancer survival by stage Available from: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stageAccessed March 16, 2015
   Google Scholar
• Cancer Research UK2011Breast cancer survival Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/survival/Accessed March 16, 2015
   Google Scholar
• American Cancer Society2015Non-small cell lung cancer Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-ratesAccessed March 16, 2015
   Google Scholar
• American Cancer Society2015Small cell lung cancer Available from: http://www.cancer.org/cancer/lungcancer-smallcell/detailedguide/small-cell-lung-cancer-survival-ratesAccessed March 16, 2015
   Google Scholar
• Cancer Research UK2011Lung cancer survival Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/Accessed March 16, 2015
   Google Scholar
• BlumRHNovetskyDShashaDFleishmanSThe multidisciplinary approach to bone metastasesOncology (Williston Park)2003176845857 discussion 862-863, 86712846127
   PubMedGoogle Scholar
• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar
• ColemanRERubensRDThe clinical course of bone metastases from breast cancerBr J Cancer198755161663814476
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• AzimHAJrde AzambujaEColozzaMBinesJPiccartMJLong-term toxic effects of adjuvant chemotherapy in breast cancerAnn Oncol20112291939194721289366
   PubMed Web of Science ®Google Scholar
• JanusNLaunay-VacherVByloosECancer and renal insufficiency results of the BIRMA studyBr J Cancer2010103121815182121063408
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Prevalence of overweight and obesity among adults with diagnosed diabetes – United States, 1988–1994 and 1999–2002MMWR Morb Mortal Wkly Rep200453451066106815549021
   PubMedGoogle Scholar
• HabibSLRojnaMDiabetes and risk of cancerISRN Oncol2013201358378623476808
   PubMedGoogle Scholar
• StengelBChronic kidney disease and cancer: a troubling connectionJ Nephrol201023325326220349418
   PubMed Web of Science ®Google Scholar
• NICE2015NICE clinical guideline 182 – Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care Available from: https://www.nice.org.uk/guidance/cg182/resources/guidance-chronic-kidney-disease-pdfAccessed September 18, 2015
   Google Scholar
• KDIGOClinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney Int Suppl201331136150
   Web of Science ®Google Scholar
• CockcroftDWGaultMHPrediction of creatinine clearance from serum creatinineNephron197616131411244564
   PubMed Web of Science ®Google Scholar
• LeveyASStevensLASchmidCHA new equation to estimate glomerular filtration rateAnn Intern Med2009150960461219414839
   PubMed Web of Science ®Google Scholar
• AaproMLaunay-VacherVImportance of monitoring renal function in patients with cancerCancer Treat Rev201238323524021605937
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industryPharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling2010 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdfAccessed July 18, 2016
   Google Scholar
• Launay-VacherVChatelutELichtmanSMWildiersHSteerCAaproMRenal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendationsAnn Oncol20071881314132117631561
   PubMed Web of Science ®Google Scholar
• Launay-VacherVOudardSJanusNPrevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) studyCancer200711061376138417634949
   PubMed Web of Science ®Google Scholar
• DharnidharkaVRKwonCStevensGSerum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysisAm J Kidney Dis200240222122612148093
   PubMed Web of Science ®Google Scholar
• BrennerBMMeyerTWHostetterTHDietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal diseaseN Engl J Med1982307116526597050706
   PubMed Web of Science ®Google Scholar
• CoreshJSelvinEStevensLAPrevalence of chronic kidney disease in the United StatesJAMA2007298172038204717986697
   PubMed Web of Science ®Google Scholar
• WeinsteinJRAndersonSThe aging kidney: physiological changesAdv Chronic Kidney Dis201017430230720610357
   PubMed Web of Science ®Google Scholar
• BergerNASavvidesPKoroukianSMCancer in the elderlyTrans Am Clin Climatol Assoc2006117147155 discussion 155–14618528470
   PubMedGoogle Scholar
• de Barros PontesLAntunesYPBuganoDDKarnakisTGiglioADKaliksRAPrevalence of renal insufficiency in elderly cancer patients in a tertiary cancer centerEinstein (Sao Paulo)201412330030325295449
   PubMedGoogle Scholar
• Launay-VacherVSpanoJPJanusNRenal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA studyCrit Rev Oncol Hematol200970212413318990585
   PubMed Web of Science ®Google Scholar
• ArellanoJHernandezRKWadeSWPrevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United StatesCancer Med20154571372025663171
   PubMed Web of Science ®Google Scholar
• BhaskaranKDouglasIForbesHdos-Santos-SilvaILeonDASmeethLBody-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adultsLancet2014384994575576525129328
   PubMed Web of Science ®Google Scholar
• AguilarEAAshrafHFrontiniMRuizMReskeTMCefaluCAn analysis of chronic kidney disease risk factors in a Louisiana nursing home population: a cross-sectional studyJ La State Med Soc2013165526026326526724350526
   PubMedGoogle Scholar
• StengelBTarver-CarrMEPoweNREberhardtMSBrancatiFLLifestyle factors, obesity and the risk of chronic kidney diseaseEpidemiology200314447948712843775
   PubMed Web of Science ®Google Scholar
• YamagataKIshidaKSairenchiTRisk factors for chronic kidney disease in a community-based population: a 10-year follow-up studyKidney Int200771215916617136030
   PubMed Web of Science ®Google Scholar
• LowranceWTOrdonezJUdaltsovaNRussoPGoASCKD and the risk of incident cancerJ Am Soc Nephrol201425102327233424876115
   PubMed Web of Science ®Google Scholar
• ButlerAMOlshanAFKshirsagarAVCancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009Am J Kidney Dis201565576377225662835
   PubMed Web of Science ®Google Scholar
• BirkelandSALokkegaardHStormHHCancer risk in patients on dialysis and after renal transplantationLancet200035592181886188710866449
   PubMed Web of Science ®Google Scholar
• SteenkampRCastledineCFeestTChapter 6 Survival and causes of death of UK adult patients on renal replacement therapy in 2010: national and centre-specific analysesNephron Clin Pract2012120Suppl 1c10513522964564
   PubMedGoogle Scholar
• FischerederMCancer in patients on dialysis and after renal transplantationNephrol Dial Transplant20082382457246018398015
   PubMed Web of Science ®Google Scholar
• AkchurinOMKaskelFUpdate on inflammation in chronic kidney diseaseBlood Purif2015391–3849225662331
   PubMed Web of Science ®Google Scholar
• JorgensenLHeuchIJenssenTJacobsenBKAssociation of albuminuria and cancer incidenceJ Am Soc Nephrol200819599299818256361
   PubMed Web of Science ®Google Scholar
• WongGHayenAChapmanJRAssociation of CKD and cancer risk in older peopleJ Am Soc Nephrol20092061341135019406977
   PubMed Web of Science ®Google Scholar
• ChristiansenCFJohansenMBLangebergWJFryzekJPSorensenHTIncidence of acute kidney injury in cancer patients: a Danish population-based cohort studyEur J Intern Med201122439940621767759
   PubMed Web of Science ®Google Scholar
• CampbellGAHuDOkusaMDAcute kidney injury in the cancer patientAdv Chronic Kidney Dis2014211647124359988
   PubMed Web of Science ®Google Scholar
• Wagrowska-DanilewiczMDanilewiczMNephrotic syndrome and neoplasia: our experience and review of the literaturePol J Pathol2011621121821574101
   PubMed Web of Science ®Google Scholar
• DavidsonMBThakkarSHixJKBhandarkarNDWongASchreiberMJPathophysiology, clinical consequences, and treatment of tumor lysis syndromeAm J Med2004116854655415063817
   PubMed Web of Science ®Google Scholar
• SeccarecciaDCancer-related hypercalcemiaCan Fam Physician2010563244246e290242 French20228307
   PubMed Web of Science ®Google Scholar
• MoreauPSan MiguelJLudwigHMultiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi13313723956208
   PubMed Web of Science ®Google Scholar
• OyajobiBOMultiple myeloma/hypercalcemiaArthritis Res Ther20079Suppl 1S4
   PubMed Web of Science ®Google Scholar
• GoldschmidtHLannertHBommerJHoADMultiple myeloma and renal failureNephrol Dial Transplant200015330130410692511
   PubMed Web of Science ®Google Scholar
• Launay-VacherVAyllonJJanusNDrug management of prostate cancer: prevalence and consequences of renal insufficiencyClin Genitourin Cancer200973E838919815487
   PubMed Web of Science ®Google Scholar
• Launay-VacherVEtessamiRJanusNLung cancer and renal insufficiency: prevalence and anticancer drug issuesLung20091871697418941834
   PubMed Web of Science ®Google Scholar
• Launay-VacherVGligorovJLe TourneauCPrevalence of renal insufficiency in breast cancer patients and related pharmacological issuesBreast Cancer Res Treat2010124374575318704681
   PubMed Web of Science ®Google Scholar
• KhafagyRShackleyDSamuelJO’FlynnKBettsCClarkeNComplications arising in the final year of life in men dying from advanced prostate cancerJ Palliat Med200710370571117592982
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation2002NKF KDOQI guidelines Available from: http://www2.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htmAccessed March 18, 2015
   Google Scholar
• ColemanRBodyJJAaproMHadjiPHerrstedtJBone health in cancer patients: ESMO Clinical Practice GuidelinesAnn Oncol201425Suppl 3iii12413724782453
   PubMed Web of Science ®Google Scholar
• GralowJRBiermannJSFarookiANCCN Task Force Report: bone health in cancer CareJ Natl Compr Canc Netw201311Suppl 3S150 quiz S51
   PubMed Web of Science ®Google Scholar
• GoldfarbSMcCulloughPAMcDermottJGaySBContrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiologyMayo Clin Proc200984217017919181651
   PubMed Web of Science ®Google Scholar
• PerazellaMAGadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosisCurr Drug Saf200831677518690983
   PubMedGoogle Scholar
• PerazellaMAMoeckelGWNephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapySemin Nephrol201030657058121146122
   PubMed Web of Science ®Google Scholar
• MillerRPTadagavadiRKRameshGReevesWBMechanisms of cisplatin nephrotoxicityToxins (Basel)20102112490251822069563
   PubMed Web of Science ®Google Scholar
• StewartDJMikhaelNZNanjiAARenal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicityJ Clin Oncol198539125112564040958
   PubMed Web of Science ®Google Scholar
• HensleyMLHagertyKLKewalramaniTAmerican Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectantsJ Clin Oncol200927112714519018081
   PubMed Web of Science ®Google Scholar
• DekkersIABlijdorpKCransbergKLong-term nephrotoxicity in adult survivors of childhood cancerClin J Am Soc Nephrol20138692292923411430
   PubMed Web of Science ®Google Scholar
• FarryJKFlombaumCDLatchaSLong term renal toxicity of ifosfamide in adult patients – 5 year dataEur J Cancer20124891326133122503397
   PubMed Web of Science ®Google Scholar
• GilbarPJRichmondJWoodJSullivanASyndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamideAnn Pharmacother2012469e2322911342
   PubMedGoogle Scholar
• WidemannBCBalisFMKempf-BielackBHigh-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaCancer2004100102222223215139068
   PubMed Web of Science ®Google Scholar
• RajkumarSVDimopoulosMAPalumboAInternational Myeloma Working Group updated criteria for the diagnosis of multiple myelomaLancet Oncol20141512e53854825439696
   PubMed Web of Science ®Google Scholar
• JolivotPAPoinsignonVPaciAA case of melphalan sustained accumulation in an 80-year old patientInt J Clin Pharm201537698498726394785
   PubMed Web of Science ®Google Scholar
• EMC+Melphalan summary of product characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/703Accessed October 1, 2015
   Google Scholar
• BirdJMFugeRSirohiBThe clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation studyBr J Haematol2006134438539016822294
   PubMed Web of Science ®Google Scholar
• HaymanSRLeungNGrandeJPGarovicVDVEGF inhibition, hypertension, and renal toxicityCurr Oncol Rep201214428529422544560
   PubMed Web of Science ®Google Scholar
• ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysisAm J Kidney Dis200749218619317261421
   PubMed Web of Science ®Google Scholar
• CrinoLDansinEGarridoPSafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyLancet Oncol201011873374020650686
   PubMed Web of Science ®Google Scholar
• PengLZhaoQYeXZhouYHuDZhengSIncidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysisPLoS One2014911e11183925365378
   PubMed Web of Science ®Google Scholar
• EMC+Opdivo summary of product characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/30476Accessed August 5, 2016
   Google Scholar
• EMC+Keytruda summary of product characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/30602Accessed August 5, 2016
   Google Scholar
• LapiFAzoulayLNiaziMTYinHBenayounSSuissaSAndrogen deprivation therapy and risk of acute kidney injury in patients with prostate cancerJAMA2013310328929623860987
   PubMed Web of Science ®Google Scholar
• ColemanREClinical features of metastatic bone disease and risk of skeletal morbidityClin Cancer Res20061220 Pt 26243s6249s17062708
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBr J Cancer20049061133113715026791
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianNSLong-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trialCancer2004100122613262115197804
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• FizaziKLiptonAMarietteXRandomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesJ Clin Oncol200927101564157119237632
   PubMed Web of Science ®Google Scholar
• LiptonAFizaziKStopeckATSuperiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsEur J Cancer201248163082309222975218
   PubMed Web of Science ®Google Scholar
• LiptonAStegerGGFigueroaJExtended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapyClin Cancer Res200814206690669618927312
   PubMed Web of Science ®Google Scholar
• NovartisZometa^® Summary of Product Characteristics2006 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdfAccessed September 18, 2016
   Google Scholar
• HoustonSGrieveRJHickishTPercivalFHamiltonERenal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional studyJ Med Econ201013116216720136578
   PubMedGoogle Scholar
• ArellanoJHauberABMohamedAFPhysicians’ preferences for bone metastases drug therapy in the United StatesValue Health2015181788325595237
   PubMed Web of Science ®Google Scholar
• Ltd. HUPamidronate disodium summary of product characteristics Available from: https://www.medicines.org.uk/emc/medicine/214422014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdfAccessed January 9, 2017
   Google Scholar
• PerazellaMAMarkowitzGSBisphosphonate nephrotoxicityKidney Int200874111385139318685574
   PubMed Web of Science ®Google Scholar
• Amgen2015XGEVA Prescribing Information Available from: http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdfAccessed September 18, 2015
   Google Scholar
• Amgen2014XGEVA Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdfAccessed September 18, 2015
   Google Scholar
• TarloffJBLashLHToxicology of the Kidney3rd edBoca Raton, FLCRC Press2004
   Google Scholar
• LameireNNephrotoxicity of recent anti-cancer agentsClin Kidney J201471112225859345
   PubMedGoogle Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20112991125113221343556
   PubMed Web of Science ®Google Scholar
• RocheAvastin Summary of Product Characterisitcs Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdfAccessed September 21, 2015
   Google Scholar
• Astellas Pharma Europe B.V. Xtandi Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002639/WC500144996.pdfAccessed September 21, 2015
   Google Scholar
• EMC+Cisplatin summary of product characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/623Accessed September 21, 2015
   Google Scholar
• EMC+Cyclophosphamide summary of product characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/29592Accessed September 21, 2015
   Google Scholar
• EMC+Ifosfamide summary of product characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/30183Accessed September 21, 2015
   Google Scholar
• EMC+Methotrexate summary of product characteristics2013 Available from: https://www.medicines.org.uk/emc/medicine/12034Accessed September 21, 2015
   Google Scholar
• Pfizer LtdSunitinib summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdfAccessed September 21, 2015
   Google Scholar
• EMC+Gentamicin summary of product characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/21665Accessed September 21, 2015
   Google Scholar
• EMC+Tobramycin summary of product characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/6566Accessed September, 21 2015
   Google Scholar
• Novartis Europharma LtdVotrient summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdfAccessed September 21, 2015
   Google Scholar
• BenoitDDHosteEAAcute kidney injury in critically ill patients with cancerCrit Care Clin201026115117919944280
   PubMed Web of Science ®Google Scholar
• SalahudeenAKDoshiSMPawarTNowshadGLahotiAShahPIncidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer centerClin J Am Soc Nephrol20138334735423243268
   PubMed Web of Science ®Google Scholar
• MirrakhimovAEVoorePKhanMAliAMTumor lysis syndrome: a clinical reviewWorld J Crit Care Med20154213013825938028
   PubMedGoogle Scholar
• EjazAAPourafsharNMohandasRSmallwoodBAJohnsonRJHsuJWUric acid and the prediction models of tumor lysis syndrome in AMLPLoS One2015103e011949725775138
   PubMed Web of Science ®Google Scholar
• WilsonFPBernsJSOnco-nephrology: tumor lysis syndromeClin J Am Soc Nephrol20127101730173922879434
   PubMed Web of Science ®Google Scholar
• HaragsimLDalalRBaggaHBastaniBKetorolac-induced acute renal failure and hyperkalemia: report of three casesAm J Kidney Dis19942445785807942813
   PubMed Web of Science ®Google Scholar
• WheltonANephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implicationsAm J Med19991065B13S24S10390124
   PubMedGoogle Scholar
• HumphreysBDSoifferRJMageeCCRenal failure associated with cancer and its treatment: an updateJ Am Soc Nephrol200516115116115574506
   PubMed Web of Science ®Google Scholar
• FinkelKWHowardSCOnco-nephrology: an invitation to a new fieldJ Clin Oncol201432222389239024934791
   PubMed Web of Science ®Google Scholar
• American Society of NephrologyOnco-nephrology forum2016 Available from: https://www.asn-online.org/about/committees/committee.aspx?panel=OncoNephAccessed June 2, 2016
   Google Scholar
• University of Texas MD Anderson Cancer CenterOnco-nephrology fellowship2016 Available from: https://www.mdanderson.org/education-and-research/education-and-training/schools-and-programs/graduate-medical-education/residency-and-fellowship-programs/onco-nephrology-fellowship.htmlAccessed June 2, 2016
   Google Scholar
• AbudayyehAALahotiASalahudeenAKOnconephrology: the need and the emergence of a subspecialty in nephrologyKidney Int20148551002100424786870
   PubMed Web of Science ®Google Scholar
• EMC+Zytiga summary of product characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/24976Accessed May 5, 2016
   Google Scholar
• EMC+Inlyta summary of product characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/27051Accessed May 5, 2016
   Google Scholar